Here's How MEDTOX Scientific May Be Failing You
Margins matter. The more MEDTOX Scientific (NAS: MTOX) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong MEDTOX Scientific's competitive position could be.
Here's the current margin snapshot for MEDTOX Scientific over the trailing 12 months: Gross margin is 42.0%, while operating margin is 7.4% and net margin is 4.6%.
Unfortunately, a look at the most recent numbers doesn't tell us much about where MEDTOX Scientific has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter (LFQ). You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for MEDTOX Scientific over the past few years.
Source: S&P Capital IQ. Dollar amounts in millions. FY = fiscal year. TTM = trailing 12 months.
Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them. To compare quarterly margins to their prior-year levels, consult this chart.
Source: S&P Capital IQ. Dollar amounts in millions. FQ = fiscal quarter.
Here's how the stats break down:
- Over the past five years, gross margin peaked at 45.3% and averaged 41.3%. Operating margin peaked at 12.5% and averaged 7.5%. Net margin peaked at 8.3% and averaged 4.7%.
- TTM gross margin is 42.0%, 70 basis points better than the five-year average. TTM operating margin is 7.4%, 10 basis points worse than the five-year average. TTM net margin is 4.6%, 10 basis points worse than the five-year average.
With recent TTM operating margins below historical averages, MEDTOX Scientific has some work to do.
Over the decades, small-cap stocks like MEDTOX Scientific have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add MEDTOX Scientific to My Watchlist.
The article Here's How MEDTOX Scientific May Be Failing You originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.